LONDON (Alliance News) - AstraZeneca PLC said Friday preliminary findings from its phase III trial of durvalumab in third line or later-stage therapy for patients with non-small cell lung cancer supports the durvalumab's clinical activity.
However, the company said it now believes it is unlikely the trial can be used for the regulatory submission of the drug as a monotherapy, although it will make that decision following a full analysis of the data.
The trial investigated the efficacy and tolerability of the drug for patients who had received at least two prior systemic treatment regimens, including platinum-based chemotherapy, and who have limited options for further therapy.
AstraZeneca said a full evaluation of the trial data is ongoing, with results to be presented at a scientific congress in 2016.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
